XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2025Three Months Ended September 30, 2024
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $1,097 $1,097 $— $994 $994 
Other— 414 414 — 412 412 
Total— 1,511 1,511 — 1,406 1,406 
Nutritional Products —    
Pediatric Nutritionals520 457 977 568 387 955 
Adult Nutritionals368 808 1,176 382 729 1,111 
Total888 1,265 2,153 950 1,116 2,066 
Diagnostic Products —     
Core Laboratory366 998 1,364 332 982 1,314 
Molecular36 95 131 37 91 128 
Point of Care111 47 158 103 43 146 
Rapid Diagnostics373 227 600 560 264 824 
Total886 1,367 2,253 1,032 1,380 2,412 
Medical Devices —    
Rhythm Management350 336 686 288 309 597 
Electrophysiology322 383 705 285 325 610 
Heart Failure280 86 366 252 70 322 
Vascular280 465 745 258 441 699 
Structural Heart297 338 635 270 288 558 
Neuromodulation196 58 254 190 46 236 
Diabetes Care 796 1,261 2,057 673 1,052 1,725 
Total2,521 2,927 5,448 2,216 2,531 4,747 
Other4 — 4 4 — 4 
Total$4,299 $7,070 $11,369 $4,202 $6,433 $10,635 
Nine Months Ended September 30, 2025Nine Months Ended September 30, 2024
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $3,121 $3,121 $— $2,910 $2,910 
Other— 1,033 1,033 — 1,016 1,016 
Total— 4,154 4,154 — 3,926 3,926 
Nutritional Products —
Pediatric Nutritionals1,695 1,377 3,072 1,646 1,377 3,023 
Adult Nutritionals1,105 2,334 3,439 1,115 2,146 3,261 
Total2,800 3,711 6,511 2,761 3,523 6,284 
Diagnostic Products —
Core Laboratory1,049 2,850 3,899 969 2,879 3,848 
Molecular111 265 376 112 272 384 
Point of Care315 133 448 308 133 441 
Rapid Diagnostics1,093 664 1,757 1,386 762 2,148 
Total2,568 3,912 6,480 2,775 4,046 6,821 
Medical Devices —
Rhythm Management994 950 1,944 851 915 1,766 
Electrophysiology943 1,091 2,034 841 983 1,824 
Heart Failure824 249 1,073 733 215 948 
Vascular831 1,381 2,212 787 1,325 2,112 
Structural Heart868 980 1,848 761 876 1,637 
Neuromodulation565 171 736 563 142 705 
Diabetes Care2,338 3,527 5,865 1,899 3,043 4,942 
Total7,363 8,349 15,712 6,435 7,499 13,934 
Other12 — 12 11 — 11 
Total$12,743 $20,126 $32,869 $11,982 $18,994 $30,976 

Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the third quarter of 2025 and 2024, COVID-19 testing-related sales totaled $69 million and $265 million, respectively. In the first nine months of 2025 and 2024, Abbott’s COVID-19 testing-related sales totaled $208 million and $571 million, respectively.
Remaining Performance Obligations

As of September 30, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $6.0 billion in the Diagnostic Products segment and $436 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 54 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2024$568 
Unearned revenue from cash received during the period382 
Revenue recognized related to contract liability balance(300)
Balance at September 30, 2025$650